Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.
Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell C, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores L, Loghavi S, DiNardo CD, Su X, Rampal RK, Bhalla KN. Fiskus W, et al. Among authors: rampal rk. Blood. 2024 Nov 19:blood.2024026388. doi: 10.1182/blood.2024026388. Online ahead of print. Blood. 2024. PMID: 39561280
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.
Patel AA, Yoon JJ, Johnston H, Davidson MB, Shallis RM, Chen EC, Burkart M, Oh TS, Iyer SG, Madarang E, Muthiah C, Gross I, Dean R, Kassner J, Viswabandya A, Madero-Marroquin R, Rampal RK, Guru Murthy GS, Bradley T, Abaza Y, Garcia JS, Gupta V, Pettit KM, Cursio JF, Odenike O. Patel AA, et al. Among authors: rampal rk. Blood Adv. 2024 Jul 9;8(13):3468-3477. doi: 10.1182/bloodadvances.2024012880. Blood Adv. 2024. PMID: 38739724 Free PMC article.
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.
Friedman JS, Durham BH, Reiner AS, Yabe M, Petrova-Drus K, Dogan A, Pulitzer M, Busam KJ, Francis JH, Rampal RK, Ulaner GA, Reddy R, Yeh R, Hatzoglou V, Lacouture ME, Rotemberg V, Mazor RD, Hershkovitz-Rokah O, Shpilberg O, Goyal G, Go RS, Abeykoon JP, Rech K, Morlote D, Fidai S, Gannamani V, Zia M, Abdel-Wahab O, Panageas KS, Rosenblum MK, Diamond EL. Friedman JS, et al. Among authors: rampal rk. Br J Haematol. 2024 Jul;205(1):127-137. doi: 10.1111/bjh.19462. Epub 2024 Apr 12. Br J Haematol. 2024. PMID: 38613141
Interferons in the treatment of myeloproliferative neoplasms.
Vachhani P, Mascarenhas J, Bose P, Hobbs G, Yacoub A, Palmer JM, Gerds AT, Masarova L, Kuykendall AT, Rampal RK, Mesa R, Verstovsek S. Vachhani P, et al. Among authors: rampal rk. Ther Adv Hematol. 2024 Feb 19;15:20406207241229588. doi: 10.1177/20406207241229588. eCollection 2024. Ther Adv Hematol. 2024. PMID: 38380373 Free PMC article. Review.
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs G, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh ST, Schiller G, McCloskey J, Palmer J, Holmes H, Hager S, Assad A, Erickson-Viitanen S, Zhou F, Daver N. Yacoub A, et al. Among authors: rampal rk. Blood Adv. 2024 Mar 26;8(6):1515-1528. doi: 10.1182/bloodadvances.2023011620. Blood Adv. 2024. PMID: 38290135 Free PMC article. Clinical Trial.
Moving toward disease modification in polycythemia vera.
Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, Rampal RK. Bewersdorf JP, et al. Among authors: rampal rk. Blood. 2023 Nov 30;142(22):1859-1870. doi: 10.1182/blood.2023021503. Blood. 2023. PMID: 37729609
74 results